• Acquired Glanzmann thrombasthenia (aGT) is generally caused by function-blocking antibodies (Abs).
Summary. Background: Acquired Glanzmann thrombasthenia (aGT) is a bleeding disorder generally caused by function-blocking anti-aIIbb3 autoantibodies. Aim: We characterize an unusual case of aGT caused by marked reduction of surface aIIbb3 with non-function-blocking anti-aIIbb3 antibodies (Abs). Methods: A 72-year-old male suffering from immune thrombocytopenia since his 50s showed exacerbation of bleeding symptom despite mild thrombocytopenia. Platelet aggregation was absent with all agonists but ristocetin. Analysis of aIIbb3 expression and genetic analysis were performed. We also analyzed effects of anti-aIIbb3 Abs of the patient on platelet function and aIIbb3 expression. Results: Surface aIIbb3 expression was markedly reduced to around 5% of normal, whereas his platelets contained aIIbb3 to the amount of 40-50% of normal. A substantial amount of fibrinogen was also detected in his platelets. There were no abnormalities in ITGA2B and ITGB3 cDNA. These results indicated that reduced surface aIIbb3 expression caused a GT phenotype, and active internalization of aIIbb3 was suggested. Anti-aIIbb3 IgG Abs were detected in platelet eluate and plasma. These Abs did not inhibit PAC-1 binding, indicating that the Abs were non-function-blocking. Surface aIIbb3 expression of a megakaryocytic cell line and cultured megakaryocytes tended to be impaired by incubation with the patient's Abs. After 2 years of aGT diagnosis, his bleeding symptom improved and surface aIIbb3 expression was recovered to 20% of normal with reduction of anti-aIIbb3 Abs. Conclusion: We demonstrated a unique aGT phenotype due to marked reduction of surface aIIbb3. Internalization
Introduction
Integrin aIIbb3 plays essential roles in thrombosis and hemostasis as a platelet receptor for fibrinogen and von Willebrand factor, and congenital defects of aIIbb3 called Glanzmann thrombasthenia (GT) cause a life-long moderate-to-severe bleeding tendency. GT platelets do not aggregate by any platelet agonists except ristocetin, which causes platelet aggregation via interaction between platelet GPIb/IX and von Willebrand factor. These aggregation defects are observed when the amount of aIIbb3 is < 20% of normal or qualitative defects of aIIbb3, and GT is classified as follows: type I with < 5% of normal, type II with 5-20%, and variant type with qualitative abnormalities [1, 2] . Although GT is caused by congenital genetic defects of ITGA2B and/or ITGB3, rare cases have been reported with GT-like platelet aggregation defects in association with autoimmune disease, such as immune thrombocytopenia (ITP), or lymphoproliferative disorders, which is referred to as acquired GT (aGT). Almost all aGT cases contain autoantibodies (autoAbs) against aIIbb3. Inhibition of adhesive receptor function of aIIbb3 by these antibodies (Abs) leads to a GT phenotype and aIIbb3 expression is not usually impaired [3] .
We now report a very unique aGT case. Although the patient suffered from ITP for more than 20 years, recent platelet counts were stable without specific medication. Nonetheless, a severe repeated bleeding symptom had recently emerged. We found GT-like aggregation defects in the patient's platelets with anti-aIIbb3 autoAbs. Unexpectedly, the GT phenotype of this patient was caused by marked reduction in surface aIIbb3 expression, not by inhibition of aIIbb3 function by anti-aIIbb3 autoAbs. Internalization of aIIbb3 induced by antibody binding appeared to be responsible, at least in part, for the GT phenotype of this case.
Materials and methods

Case
A 72-year-old Japanese man was referred to our hospital because of recent severe repeated gastrointestinal hemorrhage and epistaxis. He had been suffering from ITP concomitant with chronic thyroiditis since his 50s and been treated with corticosteroids; he underwent splenectomy and subsequently has been been treated with azathioprine, vincristine and herbal medicine in vain. At the age of 65 years, he showed cyclic thrombocytopenia with 30-300 9 10 9 /L of platelet counts every 3-4 weeks, and we previously reported the association of cyclic thrombocytopenia with the plasma thrombopoietin level, immature platelet fraction and glycocalicin levels of this patient [4] . However, the periodicity gradually disappeared and recently his platelet counts were maintained at around 80-90 9 10 9 /L without medication. Basic laboratory data are described in Table S1 . His bleeding time was highly prolonged (> 10 min) and platelet function defects were suspected. There was no family history of bleeding tendency.
Written informed consent was obtained from the patient in accordance with the Declaration of Helsinki, and this study was approved by the Osaka University Institutional Review Board (#443).
Platelet aggregation test and flow cytometry
A platelet aggregation test using platelet-rich plasma (PRP) was performed using a light transmission platelet aggregometer (Kowa PA-200C; Kowa, Tokyo, Japan). Integrin aIIbb3 activation was assessed by an activationdependent monoclonal antibody (MoAb), PAC-1, binding as previously described [5] . In brief, washed platelets suspended in Tyrode's buffer were incubated with various agonists or an aIIbb3 activating MoAb, PT25-2, along with fluorescein isothiocyanate (FITC)-PAC-1 (BD Biosciences, Franklin Lakes, NJ, USA) for 20 min, and analyzed on a flow cytometer (FACSCalibur; Becton Dickinson, Franklin Lakes, NJ, USA). Agonist-induced PAC-1 binding of a healthy control's platelets after 30-min incubation with equal amounts of the control's PRP and another healthy control's or the patient's plateletpoor plasma (PPP) was also analyzed. Platelet surface glycoprotein expression was analyzed with various anti-CD41 and CD61 MoAbs (P2, Beckman Coulter, Brea, CA, USA; 5B12, Dako, Glostrup, Denmark; IOP41a, Immunotech, Praha, Czech Republic; HIP8, BD Biosciences; VI-PL2, BD Biosciences). GPIb and GPVI expression was also assessed using anti-CD42b (HIP1, BD Biosciences) and GPVI (1G5, Biocytex, Marseille, France) MoAbs. Platelet-associated (PA) IgG was assessed with FITC-conjugated goat anti-human IgG (Invitrogen, Carlsbad, CA, USA) by flow cytometry.
Genetic analysis
Sequence analysis of the whole coding region of ITGA2B and ITGB3 cDNA was performed as previously described [5] . In brief, total RNA of platelets was extracted using TRIzol Reagent (Invitrogen). cDNA was obtained with a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). After amplification of ITGA2B or ITGB3 using primers previously described [5] , a sequence reaction was performed using a BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) according to the manufacturer's instructions. Real-time quantitative (RQ)-PCR analysis was carried out using THUNDERBIRD SYBR qPCR Mix (TOYOBO, Osaka, Japan) on QuantStudio 3 (Applied Biosystems). The reaction conditions were as follows: initial denaturation at 95°C for 1 min, 40 cycles of denaturation at 95°C for 15 sec and annealing/extension at 60°C for 1 min. The cycle threshold (CT) was determined by the analytic software (QuantStudio Design & Analysis; Applied Biosystems). The average CT number of each triplicate reaction was used in the analysis. We compared the patient's mRNA with a healthy control by DCT analysis. To assess platelet-specific ITGA2B and ITGB3 mRNAs, we adopted GP1BA mRNA as an inner control. Primer sequences for ITGA2B or ITGB3 mRNA amplification were previously described [6] . We referred primer sequences for GPIBA mRNA amplification to GP1BA Human qPCR Primer Pair (ORIGENE, Rockville, MD, USA).
Western blotting
Platelet lysates were obtained with Triton X-100 lysis buffer and separated on a 5-20% gradient gel by SDS- PAGE. aIIbb3 was detected by a mixture of a rabbit anti-CD41 MoAb (ab134131; Abcam, Cambridge, UK) and a rabbit anti-CD61 polyclonal Ab (ab197662; Abcam). After stripping, the membrane was blotted with an anti-b-actin MoAb (A-5441; Sigma-Aldrich, St Louis, MO, USA) as loading control. Quantification of aIIb and b3 was performed by comparing with serially diluted normal platelet lysates using Image J software [7] . Fibrinogen in platelet lysates was also detected by a rabbit anti-fibrinogen polyclonal Ab (A0080; Dako). Platelet lysate of a type I GT patient was used as a negative control [8] .
Detection of PA anti-aIIbb3 Abs and identification of IgG subclasses and recognition sites of the Abs Platelet eluates were obtained by diethyl ether treatment and PA anti-aIIbb3 Abs were detected as previously described [9] . In brief, platelet eluates were incubated with aIIb/pcDNA3 and b3/pcDNA3 transfected HEK293T cells on ice for 30 min. Then they were stained with Alexa Fluor488-conjugated anti-human IgG (Life Technologies, Carlsbad, CA, USA) and phycoerythrin (PE)-conjugated anti-CD61. After washing, the cells were resuspended in Tyrode's buffer that contained propidium iodine to identify dead cells and then the cells were analyzed on a flow cytometer. IgG subclasses of PA anti-aIIbb3 Abs were also determined by incubating the cells with biotin-conjugated anti-human IgG1, IgG2, IgG3 or IgG4 MoAbs (B6775, B3398, B3523 or B3648, respectively; Sigma-Aldrich), followed by staining with Alexa Fluor488-conjugated avidin (Invitrogen) and PE-anti-CD61. To test the location of the binding site of the Abs, anti-human IgG binding to human-mouse chimera aIIb co-expressed with human b3 was assessed. m(b-propeller)H expressed the entire b-propeller domain of mouse aIIb, attached to the C-terminal remainder of the protein from the human aIIb sequence, and H(b-propeller)m expressed the b-propeller domain of human aIIb attached to mouse aIIb. PA Abs binding was compensated by CD61 expression and relative binding to human aIIbb3-expressing cells was calculated. Details of the constructs and analyzation were described before [9] .
Detection of anti-aIIbb3 Abs in plasma
Anti-aIIbb3 Abs in plasma was detected by modified antigen capture ELISA (MACE) as previously described [10] . In brief, platelets of a healthy control incubated with plasma were lysed with 1% Triton-X, and aIIbb3 was captured by an anti-aIIbb3 MoAb, AP2, coated on a 96-well plate. Then, IgG bound to aIIbb3 was detected by incubation with biotin-conjugated antihuman IgG, followed by using a VECTASTAIN ABC-AP Standard Kit (Vector Laboratories, Burlingame, CA, USA).
Effect of anti-aIIbb3 Abs on aIIbb3 expression on HEL cells HEL, an aIIbb3-expressing megakaryocytic cell line, was seeded onto a 96-well plate at a concentration of 1 9 10 6 / mL in RPMI1640 (Nakarai tesque, Kyoto, Japan). Then, cells were incubated with an equal amount of platelet eluates for 24 h in a CO 2 incubator at 37°C. aIIbb3 expression in HEL cells was assessed by anti-CD61 binding on flow cytometry. In some experiments the patient's eluate was incubated with aIIbb3-transfected HEK293T cells on ice for 60 min. Then the supernatant was collected after pellet down the cells and used as anti-aIIbb3 Abs depleted eluate.
Cultured megakaryocytes from cord blood cells
After written informed consent was obtained, cord blood was obtained from healthy pregnant women after delivery. Then 3 9 10 5 of mononuclear cells (MNCs) isolated from cord blood were incubated in 800 lL serum-free medium (Stem Span SFEM, Stemcell Technologies, Vancouver, Canada) with thrombopoietin, stem cell factor, interleukin 6, interleukin 9 and human LDL (Stemcell Technologies). To investigate the effects of IgG Abs on the expression of aIIbb3 in matured megakaryocytes (MgKs), 2 mg mL À1 of IgG purified from recalcified plasma by Protein G column (GraviTrap; GE Healthcare, Boston, MA, USA) was added to mature MgKs at day 14 and incubated for another 24 h in a CO 2 incubator at 37°C. Cells were stained with FITC-anti-CD41, APCanti-CD42b and propiodium iodine, and expression of CD41 in CD42b-positive large MgKs was assessed by flow cytometry.
Statistical analysis
Data were shown as mean + SE. Analysis of statistical significance was performed with Student's t-test and P < 0.05 was considered statistically significant. 
Results
Platelet function analysis
Platelet aggregation was completely absent with ADP and collagen stimulation, whereas ristocetin induced weak aggregation (Fig. 1A) . Binding of PAC-1, an activation-dependent anti-aIIbb3 MoAb, was markedly reduced in the patient's platelets incubated with an aIIbb3-activating MoAb, PT25-2 or phorbol 12-myristate 13-acetate (PMA) (Fig. 1B) . These results indicated that aIIbb3-dependent platelet function of the patient was highly impaired, which is consistent with the GT phenotype.
Expression of platelet glycoproteins and genetic analysis
Flow cytometric analysis using an anti-CD41 MoAb, P2, and an anti-CD61 MoAb, VI-PL2, showed marked reduction of aIIbb3 expression of the patient's platelets to < 5% of the healthy control, which is comparable with GT ( Fig. 2A, left panels) . The same level of reduction of aIIbb3 expression was observed by all five different antiaIIbb3 MoAbs ( Fig. 2A, right panel) , whereas expression of GPIb and GPVI was apparently increased, probably because of increased size of the patient's platelets compared with control platelets ( Figure S1 ). These results suggest that the GT phenotype of the patient is caused by marked reduction in surface aIIbb3 expression. Next, we assessed aIIbb3 expression in whole platelets by western blotting. By sharp contrast to flow cytometry, the patient's platelets contained 40-50% of the amount of normal-sized aIIb and b3 compared with the healthy control (Fig. 2B) . We also confirmed~50% of the amount of b3 expression by western blotting using VI-PL2, which was used for flow cytometry ( Figure S2 ). Because it is known that fibrinogen is stored in platelets by aIIbb3-mediated endocytosis [11] , we next examined fibrinogen contents in platelets. A substantial amount of fibrinogen was detected in the patient's platelets, whereas fibrinogen was completely absent in type I GT platelets (Fig. 2C) . These results suggest that accelerated internalization of intact aIIbb3 may be responsible for the phenotype of the patient's platelets.
We then performed genetic analysis of the whole coding region of ITGA2B and ITGB3 cDNA obtained from the patient's platelets. However, there were no sequence abnormalities (data not shown). RQ-PCR analysis showed that the patient's platelets contain normal to near normal ITGA2B (68% of control) and ITGB3 (90% of control) mRNA. These data further suggested that the reduced expression of aIIbb3 is caused by acquired etiology.
Detection of anti-aIIbb3 IgG Abs in platelet eluate and plasma
Because the patient suffered from ITP for more than 20 years, we next analyzed anti-aIIbb3 autoAbs of the patient. We detected PA IgG on the patient's platelets by flow cytometry (Fig. 3A) . aIIbb3-specific IgG binding to aIIbb3-expressing cells was clearly detected in the patient's eluate (Fig. 3B) . We also found that PA Abs binding to type I GT platelets were reduced by~80% compared with normal platelets, indicating that the majority of PA Abs in the patient's eluate consists of anti-aIIbb3 Abs ( Figure S3 ). Anti-aIIbb3 IgG Abs were also detected in the patient's plasma by MACE (Fig. 3C) .
Effects of anti-aIIbb3 Abs on aIIbb3 function and expression
Most anti-aIIbb3 Abs reported in aGT cases impair adhesive function of aIIbb3. We analyzed the effects of the patient's plasma on aIIbb3 function of normal platelets using an activation-dependent anti-aIIbb3 MoAb, PAC-1. Interestingly, we did not detect any inhibitory effects of the patient's plasma on agonist-induced PAC-1 binding of normal platelets (Fig. 4A) .
Next, we investigated the effects of anti-aIIbb3 Abs on aIIbb3 expression. HEL cells, a megakaryocytic cell line, express endogenous aIIbb3 and surface aIIbb3 expression in HEL cells was significantly reduced to 72% of control after incubation with the patient's eluate for 24 h (Fig. 4B, left panel) . This effect was specific for the patient's anti-aIIbb3 Abs, because it was not observed in other ITP patients with anti-aIIbb3 Abs and depletion of anti-aIIbb3 Abs from the patient's eluate completely cancelled the effect (Fig. 4B , right panels, and Figure S4 ). Then, we assessed the effect of anti-aIIbb3 Abs on aIIbb3 expression of MgKs. Mature MgKs were obtained from cord blood mononuclear cells after culture with thrombopoietin, stem cell factor IL-6 and IL-9 for 14 days, and the effect of purified patient's IgG on aIIbb3 expression was assessed by flow cytometry. As shown in Fig. 4(C) , 24-h incubation of matured MgKs with the patient's IgG tended to reduce surface aIIbb3 expression compared with control IgG. However, reduction of not only aIIbb3 but also GPIb expression was observed in MgKs obtained from cord blood MNCs cultured with the patient's IgG for 14 days along with cytokines, suggesting that maturation of MgKs was also impaired by anti-aIIbb3 Abs of the patient, as reported in other ITP cases ( Figure S5 ) [12] .
IgG subclasses and epitope of anti-aIIbb3 Abs
The anti-aIIbb3 Abs of the patient appeared to be very unique, because the Abs did not inhibit aIIbb3 function but induced reduction of surface expression of aIIbb3. Then, we further analyzed characteristics of the Abs. We first analyzed IgG subclasses, and found that the PA antiaIIbb3 IgG Abs belong to IgG1 and IgG2 (Fig. 5A) . We next analyzed epitopes of the Abs. We have already reported that the majority of PA anti-aIIbb3 Abs of chronic ITP patients recognize the b-propeller domain of aIIb by using the difference of the reactivity of PA antiaIIbb3 Abs of ITP patients between human and mouse aIIbb3 [9] . PA anti-aIIbb3 Abs of this patient bound to human-mouse chimera aIIb, which expressed the entire bpropeller domain of human aIIb attached to the C-terminal remainder of the protein from the mouse aIIb to the same extent as the wild type of human aIIb (Fig. 5B, C) . By contrast, the Abs bound poorly to not only mouse aIIb but also aIIb, which consists of the b-propeller domain of mouse aIIb attached to human aIIb. These results indicate that the Abs recognized the b-propeller domain of human aIIb. More detailed epitope mapping using serial human/mouse chimera aIIb showed that the Abs mainly recognized the W3:4-1 loop in the b-propeller domain of aIIb. Thus, the epitopes of the Abs in this patient were not so unique but were located on one of the major recognition sites of anti-aIIbb3 Abs detected in chronic ITP ( Figure S6 ) [9] .
Transition of aIIbb3 expression and titer of anti-aIIbb3 Abs
The bleeding symptoms of the patient had gradually improved over the course of the observation, after diagnosis of aGT, with no interval change of platelet counts. Then, we reanalyzed aIIbb3 expression in his platelets. As expected, surface aIIbb3 expression was clearly increased compared with the previous examination and recovered to~20% of normal (Fig. 6A) . Although anti-aIIbb3 Abs were still clearly detected in his platelet eluate and plasma, reduction of the Abs titer was observed both in platelet eluate and plasma in the latest sample compared with previous samples (Fig. 6B) . These results also suggest that reduction of surface aIIbb3 expression is most probably mediated by anti-aIIbb3 Abs.
Discussion
We reported a unique aGT case associated with ITP. We found that (i) severe platelet dysfunction of the patient was caused by marked reduction (~5% of normal control) of surface aIIbb3 expression, (ii) the patient's platelets contained 40-50% of the amount of normal-sized aIIb and b3 in whole platelet lysates, (iii) a substantial amount of fibrinogen was also detected in platelet lysates, (iv) anti-aIIbb3 Abs were detected in platelet eluate and plasma and the Abs tend to reduce surface expression of aIIbb3 in a megakaryocytic cell line and cultured megakaryocytes, whereas they did not impair the aIIbb3 function of normal platelets, and (v) spontaneous recovery of surface aIIbb3 expression with reduction of antiaIIbb3 Abs titer was observed. Although we do not have direct evidence, these results suggested that anti-aIIbb3 Abs of the patient may cause reduction of surface aIIbb3 expression by internalization of aIIbb3 after Abs binding, leading to a GT phenotype (Fig. 7) . Acquired Glanzmann thrombasthenia is usually associated with anti-aIIbb3 autoAbs concomitant with autoimmune diseases or lymphoproliferative disorders, although an exceptional case with leukemia has been reported [13] . We reviewed 33 aGT cases reported in the literature so far and summarized the reported status of anti-aIIbb3 Abs and aIIbb3 expression (Table 1) . Anti-aIIbb3 Abs were detected in 27 out of 28 cases examined. Expression of aIIbb3 was reported as normal in 20 out of 25 cases and as half of control in one case [14] . In the other four cases reduced binding of some anti-aIIbb3 MoAbs by flow cytometry was reported and the authors discussed interference of the anti-aIIbb3 MoAbs binding by antiaIIbb3 autoAbs in their patients [15] [16] [17] [18] . Therefore, in these previously reported cases a GT phenotype is thought to be mostly caused by functional blocking by anti-aIIbb3 autoAbs. By contrast, the GT phenotype in our case is very unique because it is caused by marked reduction in surface aIIbb3 expression comparable to congenital GT platelets. Because similar reduction of binding was observed in all five different anti-aIIbb3 MoAbs by flow cytometry and the patient's eluate did not interfere with the binding of one of the anti-aIIbb3 MoAbs (VI-PL2) to aIIbb3 expressed in HEK293T cells (Fig. 3B) , it is very unlikely that reduction of anti-aIIbb3 MoAbs binding is caused by hindering of their binding by anti-aIIbb3 autoAbs of the patient.
Although the anti-aIIbb3 autoAbs of the patient do not cause apparent functional blocking of aIIbb3, spontaneous recovery of surface aIIbb3 expression associated with reduction of the anti-aIIbb3 autoAbs titer suggests that reduced expression of surface aIIbb3 depends on the anti-aIIbb3 autoAbs. Reduction of surface aIIbb3 expression by the patient's Abs binding was also observed in HEL cells and cultured MgKs, although the difference expression of aIIbb3 supports this hypothesis, because diethyl ether elutes not only surface-bound Abs but also internalized Abs [19] . Fibrinogen in platelets is internalized after binding of aIIbb3 [11] , and the finding that a substantial amount of fibrinogen was detected in platelet lysates of the patient also suggests that functional surface aIIbb3 may be internalized in the patient (Fig. 2C) . It is well known that integrin activation and/or clustering accelerates its internalization [20, 21] . We have already reported the discrepancy in aIIbb3 expression between surface and whole platelet lysates in aIIbb3-associated congenital macrothrombocytopenia in which constitutive activation of aIIbb3 is induced by gain-offunction mutations of ITGA2B or ITGB3 [5, 22] . However, we detected neither inhibition nor activation of aIIbb3 by anti-aIIbb3 autoAbs of the patient. We hypothesized that the patient's Abs recognize a unique epitope of aIIbb3 and performed epitope mapping as previously described [9] . However, the patient's Abs recognized common recognition sites of PA anti-aIIbb3 autoAbs detected in chronic ITP patients, suggesting that the difference in epitope does not account for the unique phenotype of the patient's platelets. We identified that IgG subclasses of PA anti-aIIbb3 autoAbs of the patient were IgG1 and IgG2, which are usual in reported aGT cases [3] . Because reduction of aIIbb3 expression was not reported in these cases, it is also unlikely that the differences of IgG subclass affect the phenotype of our patient.
We observed reduction of surface aIIbb3 expression in cultured cells by the patient's Abs. However, the effects are fairly limited and it is hard to explain the marked reduction of surface aIIbb3 expression observed in the patient by only Abs binding and acceleration of aIIbb3 internalization. Recently, Fcc-receptor-mediated removal [30] 33, F HL (CR after chemotherapy), ITP?splenectomy (+) Normal Kubota [31] 38, F NHL (+) n.d. Mayer [32] 62, F ITP post-splenectomy, Castleman disease, AIHA (+) Normal Macchi [14] 63, F ITP (PSL ineffective?splenectomy?periodic IVIg) (+) About half of control Fuse [33] 33, F Evans syndrome post-splenectomy (+) n.d. Malik [34] 53, F HL after chemo-radiotherapy PAIgM(+) Normal Thomas [35] 60, Fof surface protein after IgG Abs binding by a macrophage or neutrophil, which is called 'trogocytosis', has been reported [23, 24] . To address this possibility, we analyzed effects of addition of peripheral blood MNCs on the patient's Abs-bound HEL cells. However, reduction of surface aIIbb3 in HEL cells by incubation with MNCs was not observed ( Figure S7 ). Surface loss of platelet glycoproteins by binding of Abs is well known in cases of acquired GPVI deficiency or injection of anti-GPVI MoAb to mice [19, 25] . In these cases, surface GPVI is removed by metalloprotease-dependent shedding or internalization [25, 26] . Interestingly, removal of GPVI after Abs binding was observed only in the in vivo condition, suggesting that Abs binding is necessary but insufficient to cause GPVI removal from the platelet surface. Similarly to GPVI deficiency, unidentified factors in addition to Abs binding might be necessary to remove surface aIIbb3 in our case. Unfortunately, the patient died of an unknown cause (not bleeding) very recently, and we could not perform further investigation. In summary, we report a very unique aGT case with marked reduction of surface expression of aIIbb3. Although we could not reveal a clear mechanism of reduction of aIIbb3 expression, internalization induced by anti-aIIbb3 autoAbs appeared to be responsible at least in part for the phenotype. S1 . Assessment of platelet size of the patient. Fig. S2 . Western blotting using anti-b3 MoAb, VI-PL2. Fig. S3 . PA Abs binding to type I GT platelets. Fig. S4 . aIIbb3 expression of HEL cells after incubation with ITP patients' eluate. Fig. S5 . Effects of the patient's IgG on aIIbb3 expression of cultured MgKs. Fig. S6 . Epitope mapping of the patient's PA anti-aIIbb3 Abs. Fig. S7 . Trogocytosis of aIIbb3 in HEL cells. Table S1 . Laboratory data.
